3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine (BioDeep_00000393655)
代谢物信息卡片
3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
化学式: C21H22Cl2FN5O (449.1185)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
InChI: InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:77562
- ChEBI: CHEBI:77563
- PubChem: 11597571
- ChEMBL: CHEMBL1825138
- CAS: 877400-66-3
- PMhub: MS000244024
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Peng Zhang, JiaHua Xu, Qing Wu, Jianxin Qian, Song Wang. Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature.
Diagnostic pathology.
2024 Apr; 19(1):58. doi:
10.1186/s13000-024-01480-7. [PMID: 38616252] - Pelinsu Korucu Aktas, Ipek Baysal, Samiye Yabanoglu-Ciftci, Betul Arica. Development and In Vitro Evaluation of Crizotinib-Loaded Lipid-Polymer Hybrid Nanoparticles Using Box-Behnken Design in Non-small Cell Lung Cancer.
AAPS PharmSciTech.
2023 Sep; 24(7):178. doi:
10.1208/s12249-023-02634-4. [PMID: 37658977] - Yuyao Luo, Zhe Zhang, XuanZhu Guo, Xuemei Tang, Sijie Li, Guotao Gong, Shun Gao, Yan Zhang, Sheng Lin. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.
Lung cancer (Amsterdam, Netherlands).
2023 Aug; 184(?):107319. doi:
10.1016/j.lungcan.2023.107319. [PMID: 37597303] - Bei Zheng, Hong Jiang, Wenjuan Yang, Ying Li, Bingqing Liang, Jun Zhu, Nanmei Chen, Miao Chen, Meiling Zhang. A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.
Cancer medicine.
2023 08; 12(15):15983-15997. doi:
10.1002/cam4.6241. [PMID: 37334877] - Shujun Wang, Shuifeng Xu, Feibo Ye, Chan Zhu, Yangyang Yu, Jungang Chen. Novel LINC01923 -anaplasticlymphoma kinase rearrangement identified in advanced lung adenocarcinoma with durable response to ensartinib: a case report.
Anti-cancer drugs.
2023 08; 34(7):888-891. doi:
10.1097/cad.0000000000001467. [PMID: 36730073] - Jiqiu Qin, Ru Li, Hong Ma, Peng Ding, Qin Yang, Lilai Hu, Deliu Wu, Shaoquan Xiong. TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis.
Medicine.
2023 Jul; 102(29):e34138. doi:
10.1097/md.0000000000034138. [PMID: 37478272] - Benjamin J Solomon, Todd M Bauer, Tony S K Mok, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Yi-Long Wu, Jacek Jassem, Froylán López López, Ross A Soo, Alice T Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
The Lancet. Respiratory medicine.
2023 04; 11(4):354-366. doi:
10.1016/s2213-2600(22)00437-4. [PMID: 36535300] - Jin-Jiao Chen, Jin-Mei Jin, Wen-Jie Gu, Zeng Zhao, Hu Yuan, Yu-Dong Zhou, Dale G Nagle, Qiu-Lei Xi, Xue-Mei Zhang, Qing-Yan Sun, Ye Wu, Wei-Dong Zhang, Xin Luan. Crizotinib-based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation.
Cancer science.
2023 Jan; ?(?):. doi:
10.1111/cas.15733. [PMID: 36692137] - Han Wang, Yilan Wu, Xiaoyan Lin. Crizotinib loaded polydopamine-polylactide-TPGS nanoparticles in targeted therapy for non-small cell lung cancer.
Medical oncology (Northwood, London, England).
2022 Dec; 40(1):26. doi:
10.1007/s12032-022-01893-8. [PMID: 36459216] - Zaiqi Ma, Yun Wang, Yonghua Sun, Gaoyang Lin, Zhenqing Zhao. Efficacy of Crizotinib Combined with Chemotherapy in Treating Advanced Non-Small-Cell Lung Cancer and Effect on Patients' Quality of Life and Adverse Reaction Rate.
Journal of healthcare engineering.
2022; 2022(?):7898737. doi:
10.1155/2022/7898737. [PMID: 35310186] - Yu-Zheng He, Shan-Ling Yu, Xiao-Ning Li, Xian-Hua Bai, Hai-Tao Li, Yan-Chao Liu, Bao-Lei Lv, Xiu-Min Zhao, Dong Wei, He-Lin Zhang, Fan-Nian Li, GuoLei Li, Shuai Li. Curcumin increases crizotinib sensitivity through the inactivation of autophagy via epigenetic modulation of the miR-142-5p/Ulk1 axis in non-small cell lung cancer.
Cancer biomarkers : section A of Disease markers.
2022; 34(2):297-307. doi:
10.3233/cbm-210282. [PMID: 34957997] - Jiaolong Wang, Chunlong Sun, Min Ji, Baoqin Wang, Peng Wang, Gaoxin Zhou, Bin Dong, Wen Du, Li Huang, Hongguo Wang, Lili Ren. Design, synthesis and application of near-infrared fluorescence probe IR-780-Crizotinib in detection of ALK positive tumors.
Protein expression and purification.
2021 11; 187(?):105952. doi:
10.1016/j.pep.2021.105952. [PMID: 34375729] - Hongxia Ma, Qian Zhang, Qianqian Duan, Qin Zhang, Fengsen Li. Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment.
Lung cancer (Amsterdam, Netherlands).
2021 02; 152(?):196-198. doi:
10.1016/j.lungcan.2020.12.015. [PMID: 33386152] - Ruo-Yan Qin, Ling-Shuang Liu, Hui-Yong Zhang, Cheng-Hua Lu, Xiao-Yan Guo, Ling-Yue Zhang, Xin-Bei Yuan, Hong-Hao Xue. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
Medicine.
2021 Jan; 100(4):e24300. doi:
10.1097/md.0000000000024300. [PMID: 33530219] - Jianzhong Chen, Wei Wang, Haibo Sun, Laixue Pang, Baohua Yin. Mutation-mediated influences on binding of anaplastic lymphoma kinase to crizotinib decoded by multiple replica Gaussian accelerated molecular dynamics.
Journal of computer-aided molecular design.
2020 12; 34(12):1289-1305. doi:
10.1007/s10822-020-00355-5. [PMID: 33073300] - Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli, Holger Thurm, Anna M Calella, Gerson Peltz, Benjamin J Solomon. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
The New England journal of medicine.
2020 11; 383(21):2018-2029. doi:
10.1056/nejmoa2027187. [PMID: 33207094] - Dapeng Dong, Ge Shen, Yong Da, Ming Zhou, Gang Yang, Mingming Yuan, Rongrong Chen. Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report.
The oncologist.
2020 11; 25(11):e1720-e1724. doi:
10.1634/theoncologist.2019-0609. [PMID: 32652753] - Shu-Yue Zheng, Wen Shen, Yan-Mei Peng, Hui-Juan Cui, Hua Duan, Yu-Qin Qiu, Qiang Li, Jing-Yi Zhang, Chen-Yao Sun, Xu Zhang. Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review.
Medicine.
2018 Nov; 97(48):e13088. doi:
10.1097/md.0000000000013088. [PMID: 30508887] - Ji Woong Lim, Seok Kyu Kim, Seo Yun Choi, Dong Hoi Kim, Changdev G Gadhe, Hae Nim Lee, Hyo-Ji Kim, Jina Kim, Sung Jin Cho, Hayoung Hwang, Jihye Seong, Kyu-Sung Jeong, Jae Yeol Lee, Sang Min Lim, Jae Wook Lee, Ae Nim Pae. Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease.
European journal of medicinal chemistry.
2018 Sep; 157(?):405-422. doi:
10.1016/j.ejmech.2018.07.071. [PMID: 30103190] - Ning Zhou, Reinhold Schäfer, Tao Li, Meiyu Fang, Luying Liu. A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report.
BMC cancer.
2018 Aug; 18(1):842. doi:
10.1186/s12885-018-4749-z. [PMID: 30134855] - Feng Qiu, Yanan Gu, Tingting Wang, Yingying Gao, Xiao Li, Xiangyu Gao, Shan Cheng. Quantification and pharmacokinetics of crizotinib in rats by liquid chromatography-tandem mass spectrometry.
Biomedical chromatography : BMC.
2016 Jun; 30(6):962-8. doi:
10.1002/bmc.3636. [PMID: 26467669] - Yuanyuan Zhao, Jing Zhang, Ying Tian, Cong Xue, Zhihuang Hu, Li Zhang. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Drug design, development and therapy.
2015; 9(?):4897-907. doi:
10.2147/dddt.s85837. [PMID: 26345996] - Kimberly R Doherty, Robert L Wappel, Dominique R Talbert, Patricia B Trusk, Diarmuid M Moran, James W Kramer, Arthur M Brown, Scott A Shell, Sarah Bacus. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.
Toxicology and applied pharmacology.
2013 Oct; 272(1):245-55. doi:
10.1016/j.taap.2013.04.027. [PMID: 23707608]
